Arrakis Therapeutics’ $75 Million Series B Financing Round

Ambrogio Visconti

Goodwin advised Arrakis Therapeutics on the deal Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA,…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

…

This content is for Standard 1 Year members only.
Login Join Now